Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study of the Safety, Tolerability and Immunogenicity of GLS-5310 DNA Vaccine Against SARS-CoV-2

NCT05085639 is registered in ClinicalTrials.gov with GeneOne Life Science, Inc. as lead sponsor.

NCT NCT05085639
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05085639 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study of the Safety, Tolerability and Immunogenicity of GLS-5310 DNA Vaccine Against SARS-CoV-2
Lead sponsor
GeneOne Life Science, Inc.
Phase
Phase 1
Overall status
Unknown status
Start date
November 30, 2021
Completion date
December 31, 2022
Enrollment
30 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

covid19, healthy